Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:8073926rdf:typepubmed:Citationlld:pubmed
pubmed-article:8073926lifeskim:mentionsumls-concept:C0376358lld:lifeskim
pubmed-article:8073926lifeskim:mentionsumls-concept:C0194810lld:lifeskim
pubmed-article:8073926lifeskim:mentionsumls-concept:C1517927lld:lifeskim
pubmed-article:8073926lifeskim:mentionsumls-concept:C0600558lld:lifeskim
pubmed-article:8073926lifeskim:mentionsumls-concept:C0205210lld:lifeskim
pubmed-article:8073926lifeskim:mentionsumls-concept:C0205179lld:lifeskim
pubmed-article:8073926pubmed:dateCreated1994-9-29lld:pubmed
pubmed-article:8073926pubmed:abstractTextThirty-five patients underwent a protocol of neo-adjuvant hormonal suppression previous to radical surgery in locally advanced stages, seven patients in stage B (T2) and 25 in stage C (T3). Three cases were not considered suitable for surgery since no clinical evidence of sub-staging was demonstrated. Clinical reassessment after neo-adjuvant therapy was conducted by rectal examination, PSA and transrectal ultrasound. Pre-hormonal average of PSA was 38.20 ng/ml (range: 1-235). Post-hormonal average was 1.15 ng/ml (range < 0.5-6.2). Clinical reduction of prostate volume was seen in 75% of patients. In three of them (9.37%) no tumour (Po) was seen in the pieces of prostatectomy.lld:pubmed
pubmed-article:8073926pubmed:languagespalld:pubmed
pubmed-article:8073926pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8073926pubmed:citationSubsetIMlld:pubmed
pubmed-article:8073926pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8073926pubmed:statusMEDLINElld:pubmed
pubmed-article:8073926pubmed:monthMaylld:pubmed
pubmed-article:8073926pubmed:issn0210-4806lld:pubmed
pubmed-article:8073926pubmed:authorpubmed-author:Villavicencio...lld:pubmed
pubmed-article:8073926pubmed:authorpubmed-author:LagunaPPlld:pubmed
pubmed-article:8073926pubmed:authorpubmed-author:Ponce de...lld:pubmed
pubmed-article:8073926pubmed:issnTypePrintlld:pubmed
pubmed-article:8073926pubmed:volume18 Suppllld:pubmed
pubmed-article:8073926pubmed:ownerNLMlld:pubmed
pubmed-article:8073926pubmed:authorsCompleteYlld:pubmed
pubmed-article:8073926pubmed:pagination404-8lld:pubmed
pubmed-article:8073926pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:8073926pubmed:meshHeadingpubmed-meshheading:8073926-...lld:pubmed
pubmed-article:8073926pubmed:meshHeadingpubmed-meshheading:8073926-...lld:pubmed
pubmed-article:8073926pubmed:meshHeadingpubmed-meshheading:8073926-...lld:pubmed
pubmed-article:8073926pubmed:meshHeadingpubmed-meshheading:8073926-...lld:pubmed
pubmed-article:8073926pubmed:meshHeadingpubmed-meshheading:8073926-...lld:pubmed
pubmed-article:8073926pubmed:meshHeadingpubmed-meshheading:8073926-...lld:pubmed
pubmed-article:8073926pubmed:meshHeadingpubmed-meshheading:8073926-...lld:pubmed
pubmed-article:8073926pubmed:meshHeadingpubmed-meshheading:8073926-...lld:pubmed
pubmed-article:8073926pubmed:meshHeadingpubmed-meshheading:8073926-...lld:pubmed
pubmed-article:8073926pubmed:meshHeadingpubmed-meshheading:8073926-...lld:pubmed
pubmed-article:8073926pubmed:year1994lld:pubmed
pubmed-article:8073926pubmed:articleTitle[Clinical impact of neoadjuvant treatment to radical prostatectomy in locally advanced prostatic cancer].lld:pubmed
pubmed-article:8073926pubmed:affiliationFundación Puigvert, Barcelona.lld:pubmed
pubmed-article:8073926pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:8073926pubmed:publicationTypeEnglish Abstractlld:pubmed
pubmed-article:8073926pubmed:publicationTypeReviewlld:pubmed